Literature DB >> 7397053

Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).

A B Atkinson, D McAreavey, G Trope.   

Abstract

A patient developed papilloedema and hepatic dysfunction while being treated with perhexiline maleate. These later regressed when the drug was withdrawn. Patients should be monitored for these potentially serious side-effects while on this drug.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7397053      PMCID： PMC482324          DOI： 10.1136/hrt.43.4.490

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


  4 in total

1.  [Peripheral neuropathies caused by perhexiline maleate. Apropos of 7 cases].

Authors:  M G Bousser; P Bouche; C Brochard; G Herreman
Journal:  Coeur Med Interne       Date:  1976 Apr-Jun

2.  Proximal myopathy after perhexiline maleate treatment.

Authors:  I W Tomlinson; F D Rosenthal
Journal:  Br Med J       Date:  1977-05-21

3.  Papilloedema in patients taking perhexiline maleate.

Authors:  W M Hutchinson; J Williams; J Gawler
Journal:  Br Med J       Date:  1978-02-04

4.  Raised intracranial pressure due to perhexiline maleate.

Authors:  W P Stephens; J D Eddy; L M Parsons; S P Singh
Journal:  Br Med J       Date:  1978-01-07
  4 in total
  4 in total

1.  Pseudotumor cerebri with amiodarone.

Authors:  B G Fikkers; J Bogousslavsky; F Regli; S Glasson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-05       Impact factor: 10.154

Review 2.  The clinical spectrum of amiodarone-associated optic neuropathy.

Authors:  Lenworth N Johnson; Gregory B Krohel; Eric R Thomas
Journal:  J Natl Med Assoc       Date:  2004-11       Impact factor: 1.798

3.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30

Review 4.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.